BlackRock
SRRA

BlackRock’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

BlackRock’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,169,751
Closed -$64.3M – 6052
2022
Q2 		$64.3M Buy
1,169,751
+721,321
+161% +$37.9M ﹤0.01% 2317
2022
Q1 		$14.4M Buy
448,430
+424,985
+1,813% +$12.2M ﹤0.01% 3378
2021
Q4 		$509K Buy
23,445
+2,988
+15% +$65.8K ﹤0.01% 4868
2021
Q3 		$448K Sell
20,457
-1,031
-5% -$20.6K ﹤0.01% 4784
2021
Q2 		$419K Buy
21,488
+17,303
+413% +$314K ﹤0.01% 4735
2021
Q1 		$72K Buy
4,185
+2,429
+138% +$38.5K ﹤0.01% 4876
2020
Q4 		$28K Sell
1,756
-2,684
-60% -$37.3K ﹤0.01% 4743
2020
Q3 		$47K Buy
4,440
+435
+11% +$5.18K ﹤0.01% 4621
2020
Q2 		$48K Buy
+4,005
New +$49.7K ﹤0.01% 4590
2018
Q3 		– Sell
-144
Closed -$17K – 5111
2018
Q2 		$17K Buy
+144
New +$14.4K ﹤0.01% 4699

Other funds holding SRRA

HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

BlackRock's SRRA Position: Q3 2022 in Review

BlackRock sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 1,169,751 shares — an estimated $64.3M sold.

BlackRock first reported a position in SRRA in Q2 2018 and held it in 10 quarters. The position peaked at $64.3M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • BlackRock reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • BlackRock sold 1,169,751 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $64.3M.
  • BlackRock first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
  • BlackRock's Sierra Oncology, Inc. Common Stock position peaked at $64.3M in Q2 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.